HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

YLT256

has antineoplastic activity; structure in first source

Also Known As:

4-(((5-amino-1,3,4-thiadiazol-2-yl)thio)methyl)-N-(4-(trifluoromethyl)phenyl)benzamide

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Deng, Hongxia: 1 article (07/2016)
2.	Gao, Tiantao: 1 article (07/2016)
3.	Shi, Yaojie: 1 article (07/2016)
4.	Song, Xuejiao: 1 article (07/2016)
5.	Wang, Ningyu: 1 article (07/2016)
6.	Xia, Yong: 1 article (07/2016)
7.	Ye, Tinghong: 1 article (07/2016)
8.	Yu, Luoting: 1 article (07/2016)
9.	Zeng, Jun: 1 article (07/2016)
10.	Zhang, Lidan: 1 article (07/2016)

Related Diseases

1.	Pancreatic Neoplasms (Pancreatic Cancer) 07/01/2016 - "Together, all the results of present study provided evidence demonstrating that YLT256 could be a promising potential drug candidate for pancreatic cancer therapy. " 07/01/2016 - "In this study, we found that YLT256 showed growth inhibition against a broad spectrum of human cancer cell lines and pancreatic cancer cell line BxPc-3 was the most sensitive with an IC50 of 0.42μM. "
2.	Neoplasms (Cancer) 07/01/2016 - "Furthermore, our data also revealed that YLT256 suppressed the growth of established tumor-bearing xenograft models without obvious side effects. " 07/01/2016 - "A novel small-molecule YLT256 inhibits proliferation and induces apoptosis both in vitro and in vivo in solid tumors." 07/01/2016 - "In this study, we found that YLT256 showed growth inhibition against a broad spectrum of human cancer cell lines and pancreatic cancer cell line BxPc-3 was the most sensitive with an IC50 of 0.42μM. "

Related Therapies and Procedures

1.	Therapeutics